Pierre A. Van Damme
Expertise in
20
conditions

Pierre A. Van Damme

Antwerpen, VLG, BE 
Expertise in
20
conditions
Antwerpen, VLG, BE 

Overview

Pierre Van Damme practices practicing medicine in Antwerpen, Belgium.

Mr. Van Damme is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Pertussis, Hepatitis A, Tetanus, and Human Papillomavirus Infection.

He is actively involved in clinical research, co-authoring 280 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Antwerpen, VLG, Belgium
Other Locations
Wilrijk, VLG 2610, Belgium
Edegem, VLG, Belgium
Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Placebo-controlled Trial to Evaluate the Optimal Dose of MV-LASV, a New Vaccine Against LASSA Virus Infection, Regarding Safety, Tolerability & Immunogenicity in Healthy Volunteers Consisting of an Unblinded Dose Escalation & an Observer-blinded Treatment Phase
A Randomized, Placebo-controlled Trial to Evaluate the Optimal Dose of MV-LASV, a New Vaccine Against LASSA Virus Infection, Regarding Safety, Tolerability & Immunogenicity in Healthy Volunteers Consisting of an Unblinded Dose Escalation & an Observer-blinded Treatment Phase
Enrollment Status: Completed
Publish Date: July 11, 2025
Intervention Type: Biological, Other
Study Phase: Phase 1
Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?
Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?
Enrollment Status: Completed
Publish Date: March 06, 2023
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years.
A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years.
Enrollment Status: Completed
Publish Date: September 22, 2022
Intervention Type: Biological
Study Phase: Phase 1
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
Developing Methods to Investigate Additional Opportunities of HPV Vaccination, Including Control of Infection and Transmission, by Using a Cervicovaginal Human Sample, Collected by Urination (HPV-VACPLUS)
Developing Methods to Investigate Additional Opportunities of HPV Vaccination, Including Control of Infection and Transmission, by Using a Cervicovaginal Human Sample, Collected by Urination (HPV-VACPLUS)
Enrollment Status: Completed
Publish Date: September 29, 2021
Intervention Type: Other
Immunogenicity and Safety of HBAI20 Hepatitis B Vaccine in Non-responders
Immunogenicity and Safety of HBAI20 Hepatitis B Vaccine in Non-responders
Enrollment Status: Completed
Publish Date: January 31, 2019
Intervention Type: Biological
Study Phase: Phase 2
View 5 Less Clinical Trials

280 Total Publications

Overview of adult immunization in Finland: Successes, lessons learned and the way forward.
Overview of adult immunization in Finland: Successes, lessons learned and the way forward.
Journal: Human vaccines & immunotherapeutics
Published: August 26, 2026

Frequently Asked Questions about Pierre A. Van Damme

Is Pierre A. Van Damme a top-rated expert for Pertussis?

MediFind is an objective health platform that identifies experts based on real-world data. Pierre A. Van Damme is classified as an Elite expert for Pertussis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Pierre A. Van Damme participate in research or clinical trials?

Yes. Pierre A. Van Damme has published 280 articles and abstracts on conditions like Pertussis. You can view a list of Pierre A. Van Damme's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Van Damme's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile